NASDAQ:LEGN 31 May 2026

Legence Shares Fall Despite S&P Ratings Bump

Legence Shares Fall Despite S&P Ratings Bump

Legence Corp. lost 5.9% to end at $83.69 on Friday, with shares closing near session lows as growth-heavy industrials sold off across the U.S. The building systems stock was flat in after-hours trading following the regular close at 4 p.m. Legence Holdings LLC picked up an upgrade to BB- from B+ at S&P Global Ratings late Friday, with the agency pointing to lower private-equity sponsor ownership and better-than-expected first-quarter numbers. S&P also shifted its outlook to positive. The new BB- is still below investment grade, so lenders still see higher risk than with investment-grade firms. But it’s a notch up the scale.
June 6, 2026
Legend Biotech Heads Into Monday After a Rough Week, ASCO in Focus

Legend Biotech Heads Into Monday After a Rough Week, ASCO in Focus

Legend Biotech shares are on a four-day losing streak on Nasdaq as the new week begins. Investors are watching for a Sunday evening cancer conference event that could be key for the stock’s direction. Legend Biotech shares ended Friday at $27.16, losing 3.89% on the session. The stock is now trading about 7.5% lower than the previous Friday’s close of $29.37. U.S. markets saw a shortened week due to the Memorial Day holiday. Nasdaq is closed Sundays and trades Monday to Friday, 9:30 a.m. to 4 p.m. ET.
May 31, 2026